Research and development

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Tuesday, March 26, 2024
Ovarian cancer, Cyclin, IND, Therapy, Anemia, Research, University, Cell cycle, MD Anderson Cancer Center, PLK1, DDR, Investigational New Drug, Safety, Pharmacokinetics, Synthetic lethality, WEE1, U.S. FDA, Mutation, Acceleration, Part, HERG, ATR, KOL, Acquisition, Cancer, AACR, Research and development, Poster, FDA, Cyclin E, Toxicity, Aplastic anemia, Administration, Conference, APRE, PLK3, PLK2, Division, Data, Cardiotoxicity, Pharmaceutical industry

DOYLESTOWN, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Key Points: 
  • “Aprea had a very productive 2023 with significant progress across our diversified pipeline of synthetic lethality-based cancer therapeutics.
  • An update from Part 1 of the trial was featured in a poster presentation at the AACR-NCI-EORTC International Conference in October 2023.
  • Select Financial Results for the Fourth Quarter ended December 31, 2023
    As of December 31, 2023, Aprea reported cash and cash equivalents of $21.6 million.
  • Research and Development (R&D) expenses were $2.0 million for the quarter ended December 31, 2023, compared to $0.5 million for the fourth quarter of 2022.

Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Neuroscience, Juno Therapeutics, Genentech, Cornell University, Heredity, Patient, Carmustine, Acquisition, Allergy, Senior, Research and development, Therapy, Drug development, Rituximab, Management

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors.
  • Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience.
  • “It is a pleasure to welcome Sunil to our Board of Directors,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics.
  • “STAR-0215 has the potential to significantly improve the lives of patients and I look forward to contributing to its progress at this exciting time.”
    Dr. Agarwal currently serves on the Board of Directors of Arvinas and was previously a Board member of Calithera Biosciences, MyoKardia, and Vitrisa Therapeutics.

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Depression, Eli Lilly, Major depressive disorder, Patient, Bristol Myers Squibb, PureTech Health, PRTC, Therapy, Creativity, Disorder, General counsel, CNS, Life, DSM-IV codes, Pleasure, Pharmacokinetics, Interim, Third Rock Ventures, U.S. FDA, Schizophrenia, KarXT, Teva Pharmaceuticals, ARCH Venture Partners, Merck, Anxiety, Merck & Co., Research and development, FDA, Lymphatic system, Hepatotoxicity, Sirna Therapeutics, Generalized anxiety disorder, Growth, Neuropsychiatry, Partner, Multimedia, Eli Lilly and Company, Probability, Liver, Medicine, Pharmaceutical industry

Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.

Key Points: 
  • Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.
  • Under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.
  • Eric Elenko, Ph.D., a PureTech co-founder and current Chief Innovation Officer, has been promoted to the role of President of PureTech.
  • Daphne Zohar, the Chief Executive Officer of Seaport, is the founder and former CEO of PureTech Health where she also co-founded Karuna Therapeutics.

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Health, Neurology, General Health, Pharmaceutical, Biotechnology, Generalized anxiety disorder, Depression, Eli Lilly, U.S. FDA, Schizophrenia, KarXT, Major depressive disorder, ARCH Venture Partners, Patient, CNS, Anxiety, Bristol Myers Squibb, PureTech Health, DSM-IV codes, Pleasure, Neuropsychiatry, Research and development, Therapy, Pharmacokinetics, Partner, Disorder, Third Rock Ventures, Probability, FDA, Lymphatic system, Hepatotoxicity, Liver, Medicine, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.
  • The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health.
  • Seaport is advancing a clinical-stage pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph™ Technology Platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms.
  • I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.”

Communication Test and Measurement Market worth $14.9 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, April 8, 2024
Viavi Solutions, LitePoint, POC, Telecom, Telecommunications, Consultant, MIMO, Lab, Rohde & Schwarz, BERT, Measurement, Anomaly, IEEE 802.11be, NetScout Systems, Keysight, FR3, ROI, OTA, Distortion, Communication, RF, Radio frequency, Smartphone, Growth, MediaTek, Spirent, FR1, Research and development, Hertz, Hardware

In the dynamic landscape of the Communication Test and Measurement Market, an array of specialized software plays a pivotal role in ensuring the seamless functionality and robust performance of communication networks.

Key Points: 
  • In the dynamic landscape of the Communication Test and Measurement Market, an array of specialized software plays a pivotal role in ensuring the seamless functionality and robust performance of communication networks.
  • To determine, segment, and forecast the global Communication Test and Measurement Market based on offering, test solution, type of test, end user, and region in terms of value.
  • To analyze the industry trends, patents, and innovations related to the Communication Test and Measurement Market.
  • To analyze the opportunities for stakeholders by identifying the high-growth segments of the Communication Test and Measurement Market.

Communication Test and Measurement Market worth $14.9 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, April 8, 2024
Viavi Solutions, LitePoint, POC, Telecom, Telecommunications, Consultant, MIMO, Lab, Rohde & Schwarz, BERT, Measurement, Anomaly, IEEE 802.11be, NetScout Systems, Keysight, FR3, ROI, OTA, Distortion, Communication, RF, Radio frequency, Smartphone, Growth, MediaTek, Spirent, FR1, Research and development, Hertz, Hardware

In the dynamic landscape of the Communication Test and Measurement Market, an array of specialized software plays a pivotal role in ensuring the seamless functionality and robust performance of communication networks.

Key Points: 
  • In the dynamic landscape of the Communication Test and Measurement Market, an array of specialized software plays a pivotal role in ensuring the seamless functionality and robust performance of communication networks.
  • To determine, segment, and forecast the global Communication Test and Measurement Market based on offering, test solution, type of test, end user, and region in terms of value.
  • To analyze the industry trends, patents, and innovations related to the Communication Test and Measurement Market.
  • To analyze the opportunities for stakeholders by identifying the high-growth segments of the Communication Test and Measurement Market.

RADCOM Announces a CEO Transition

Retrieved on: 
Friday, April 5, 2024
Executive, Radcom Ltd, Growth, TEL, RadCom, Research and development, Management

TEL AVIV, Israel, April 5, 2024 /PRNewswire/ -- RADCOM Ltd. (Nasdaq: RDCM) announced today that the Board has appointed Mr. Hilik Itman as interim CEO, effective April 7, 2024.

Key Points: 
  • TEL AVIV, Israel, April 5, 2024 /PRNewswire/ -- RADCOM Ltd. (Nasdaq: RDCM) announced today that the Board has appointed Mr. Hilik Itman as interim CEO, effective April 7, 2024.
  • Guy Shemesh, who assumed the CEO role in mid-February, is stepping down, effective April 7, 2024, due to personal reasons.
  • "With my support, Hilik, the entire management team, and all the board members will ensure a seamless transition until we nominate a permanent CEO.
  • Ms. Heli (Rachel) Bennun concluded: "RADCOM remains fully committed to enhancing profitability and growth, continuing the positive momentum of the past four years."

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, March 25, 2024
Rated R, Fulvestrant, KICKSTART, Patient, Sale, G&A, Investment, Therapy, Anemia, Vomiting, Artificial intelligence, Effector, Research, Science, AML, Expense, Pembrolizumab, Breast cancer, Safety, Fatigue, PD-L1, Database, NSCLC, Associate, Cancer, University, PFS, Hematology, FDA, OS, Azacitidine, ZF, Administration, Assistant, MNK, Progression-free survival, COVID-19, Fast Track, Messenger, Cell, Nausea, Research and development, DARPA, Interval (mathematics), Pharmaceutical industry

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • The primary analysis will reflect 37 PFS events, which provides approximately 80% power to detect a PFS hazard ratio of 0.65 at a p≤0.2.
  • Revenue: Revenue was zero for the quarter ended December 31, 2023, compared to approximately $0.7 million for the same quarter of 2022.
  • Research and Development (R&D) Expenses: R&D expenses were $6.1 million for the quarter ended December 31, 2023, compared to $6.6 million for the same quarter of 2022.
  • The earn-out period expired in August 2023 resulting in a reduction of the corresponding earn-out liability to zero as of December 31, 2023.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Innodata Inc. - INOD

Retrieved on: 
Saturday, March 23, 2024
Research, Prior, Innodata, News, Ext, LLP, AI, Nature, Complaint, Pomerantz, Research and development, Action Replay, Wolfpack, Court

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Innodata Inc. (“Innodata” or the “Company”) (NASDAQ: INOD).

Key Points: 
  • NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Innodata Inc. (“Innodata” or the “Company”) (NASDAQ: INOD).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • The class action concerns whether Innodata and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Innodata, Fox Factory, Lantronix, and Palo Alto Networks and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 22, 2024
Research, Class Action, Growth, Palo Alto Networks, Intelligence, Federation, EPS, Internet of things, PANW, Defendant, Internet, News, Transport, AI, Nature, Complaint, Silicon, City, P.C, Goldengate, Research and development, Fox Factory, Wolfpack, Marketing

Innodata also stopped disclosing its Research and Development spend after the first quarter of 2021.

Key Points: 
  • Innodata also stopped disclosing its Research and Development spend after the first quarter of 2021.
  • On this news, the price of Innodata common stock declined by $3.74 per share, or approximately 30.5%, on February 15, 2024.
  • The complaint further alleges that when these misleading statements and omissions about Fox Factory’s business reached the market, investors were harmed significantly.
  • For more information on the Palo Alto Networks class action go to: https://bespc.com/cases/PANW